Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jul 2019 to Jul 2024
Wageningen University and Research Centre, a leading organization in the
field of life sciences and natural resources with focus on healthy food
production, biodiversity, and sustainable production chains, and Luminex
Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed
solutions, today announced that they have signed a licensing agreement
to provide Wageningen UR access to Luminex's xMAP®
technology and the Luminex Bioscience Group’s
assay development capabilities.
Under the terms of the agreement, Wageningen UR will utilize Luminex's
xMAP technology in selected areas of Agro Biotechnology. Focus
application areas are expected to include plant pathogen detection,
epidemiology, food safety, and marker assisted plant and animal breeding
programs. The demand for fast multiplex testing, or performing multiple
tests on a single sample, continues to accelerate in Agro Biotechnology
markets.
"Providing our customers with access to a proven multiplexing solution
is essential to assist specific research and development needs and for
long-term growth," said Raoul Bino, Professor Plant Metabolomics and
director of the Plant Sciences Group of Wageningen UR. "We have selected
Luminex's xMAP technology as a recognized industry benchmark in life
science research and multiplex diagnostics applications. We look forward
to working closely and collaboratively with Luminex to benefit our
respective customers."
Douglas Bryant, executive vice president and chief operating officer at
Luminex Corporation, commented, "This agreement with Wageningen UR is a
prime example of Luminex's growing emphasis on establishing long-term
partnerships and collaborations with market leaders in segments of
strategic significance to Luminex. In this relationship with Wageningen
UR, we are not only providing new markets and customers with access to
the Luminex xMAP technology, we also are partnering with a recognized
knowledge organization with significant experience in Agro Biotechnology
markets. We are excited to have Wageningen UR on board, and look forward
to pursuing additional collaborative opportunities with them in the
future."
About Luminex Corporation
Luminex Corporation develops, manufactures and markets proprietary
biological testing technologies with applications throughout the
diagnostic and life sciences industries. The Company's xMAP®
multiplex solutions include an open-architecture, multi-analyte
technology platform that delivers fast, accurate and cost-effective
bioassay results to markets as diverse as pharmaceutical drug discovery,
clinical diagnostics and biomedical research, including the genomics and
proteomics markets. The Company's xMAP technology is sold worldwide and
is already in use in leading clinical laboratories as well as major
pharmaceutical, diagnostic and biotechnology companies. Further
information on Luminex Corporation or xMAP can be obtained at www.luminexcorp.com.
About Wageningen UR
Wageningen UR is a collaboration between Wageningen University, Van Hall
Larenstein School of Higher Professional Education and the specialised
former research institutes (DLO) from the Dutch Ministry of Agriculture.
This combination of knowledge and experience enables Wageningen UR with
its 5.600 staff and more than 8.500 students to contribute actively to
solving scientific, social and commercial problems in the field of life
sciences and natural resources. Wageningen UR approaches these national
and international issues from the perspectives of various disciplines,
with an integrated approach and in close collaboration with governments,
companies, stakeholder organisations, citizens, and other
knowledge institutions. We pay attention to the balance between three
priorities in society: economics, culture and nature.